Phase 1B Study of PD-0332991 in Combination With T-DM1 in the Treatment of Patients With Advanced HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Breast Cancer

Trial Profile

Phase 1B Study of PD-0332991 in Combination With T-DM1 in the Treatment of Patients With Advanced HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs Palbociclib (Primary) ; Trastuzumab emtansine
  • Indications Breast cancer; Male breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2020.
    • 16 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top